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Apoptosis serves as a powerful defense against damaged or pathogen-infected cells. Since apoptosis is an
effective defense against viral infection, many viruses including poxviruses, encode proteins to prevent
or delay apoptosis. Here we show that ectromelia virus, the causative agent of mousepox encodes an
anti-apoptotic protein EVM025. Here we demonstrate that expression of functional EVM025 is crucial to
prevent apoptosis triggered by virus infection and staurosporine. We demonstrate that the expression of
EVM025 prevents the conformational activation of the pro-apoptotic proteins Bak and Bax, allowing the
maintenance of mitochondrial membrane integrity upon infection with ECTV. Additionally, EVM025
interacted with intracellular Bak. We were able to demonstrate that EVM025 ability to inhibit Bax
activation is a function of its ability to inhibit the activity of an upstream BH3 only protein Bim.
Collectively, our data indicates that EVM025 inhibits apoptosis by sequestering Bak and inhibiting the
activity of Bak and Bax.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Apoptosis, also known as programmed cell death, is a tightly
regulated mechanism of cell death that is critical for the disposal of
unwanted cells and defense against pathogen infection (Gerschenson
and Rotello, 1992; McIlwain et al., 2013; Taylor et al., 2008). Apoptosis
can be triggered through two distinct pathways, the extrinsic and the
intrinsic pathway. The mitochondrion acts as a critical control point
for the intrinsic pathway (Green, 2005; Tait and Green, 2010). During
cellular stress leading to intrinsic apoptosis, mitochondria undergo a
loss of the mitochondrial outer membrane potential (MOMP) and
release death promoting proteins such as cytochrome c, SMAC/
Diablo, and Omi/Htr2A (Chipuk et al., 2010; Cleland et al., 2010;
Hengartner, 2000). These death promoting molecules result in the
activation of the apoptosome leading to cell death (Cullen and
Martin, 2009; Green, 2005; McIlwain et al., 2013).
The mitochondrial pathway is controlled by both pro- and anti-
apoptotic members of the Bcl-2 family that are characterized by
the presence of Bcl-2 homology (BH) domains (Chipuk et al., 2010;
Taylor et al., 2008). Anti-apoptotic Bcl-2 proteins including Bcl-2,
Bcl-xL, Mcl-1, Bcl-w, and A1 (Chipuk et al., 2010). Members of the
anti-apoptotic Bcl-2 family contain a mitochondrial targeting
sequence that functions to localize it to the mitochondria. Bak
and Bax are two pro-apoptotic proteins that play a pivotal role in
triggering apoptosis, these are frequently kept inactive by anti-
apoptotic members such as Bcl-2, Bcl-xL, and Mcl-1 (Westphal
et al., 2011; Wolter et al., 1997). In the absence of an apoptotic
stimulus Bax is predominantly found in the cytoplasm or loosely
associated with intracellular membranes. Upon activation Bax under-
goes a conformational change that exposes the N-terminus, and Bax
re-localizes to the outer mitochondria membrane (Annis et al., 2005;
Antonsson et al., 1997; Wolter et al., 1997). In contrast, Bak is
normally found associated with the outer mitochondrial membrane.
Once activated, Bak and Bax form high molecular weight homo-
oligomers that facilitate the release of molecules like cytochrome
c and SMAC/Diablo (Antignani and Youle, 2006; Cleland et al., 2011;
Karbowski et al., 2006). Cells deﬁcient in Bax and Bak are protected
from mitochondrial apoptosis (James et al., 2007).
Since apoptosis is an important anti-viral defense it is not
surprising that many viruses have developed strategies to prevent
or delay apoptosis (Benedict et al., 2002; Teodoro and Branton, 1997).
For example, a number of viruses encode Bcl-2 homologs that
function at the mitochondria and inhibit the release of cytochrome
c (Cuconati and White, 2002; Galluzzi et al., 2008; Polster et al.,
2004). Additionally, several viruses encode mitochondrial proteins
that inhibit apoptosis, but lack obvious sequence homology with the
cellular Bcl-2 family members; these include K7, encoded by Kaposi's
sarcoma virus, and vMIA, encoded by human cytomegalovirus
(Cuconati and White, 2002; Kuida et al., 1995; Polster et al., 2004).
The Poxviridae are large DNA viruses that encode multiple proteins
that interfere with cell signaling pathways. Importantly, poxviruses
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encode many anti-apoptotic proteins, including M11L from myxoma
virus, FPV039 from fowlpox virus, DPV002 from deerpox virus,
SPPV014 from sheeppox virus, and CrmA encoded by cowpox virus
(Banadyga et al., 2007, 2011; Everett et al., 2000; Miura et al., 1995;
Okamoto et al., 2012; Taylor and Barry, 2006). Cowpox virus-encoded
cytokine response modiﬁer A (CrmA), also known as Spi-2, inhibits
both Fas- and tumor necrosis factor (TNF) induced apoptosis by
inhibiting the activity of caspase 1 and caspase 8 (Dbaibo et al., 1997;
Miura et al., 1995). Previously, our lab identiﬁed F1L, a unique anti-
apoptotic protein encoded by vaccinia virus (VACV) (Wasilenko et al.,
2003). F1L localizes to the outer mitochondrial membrane and
inhibits cytochrome c release in response to a wide variety of
apoptotic stimuli (Stewart et al., 2005; Wasilenko et al., 2005).
Although F1L lacks obvious sequence homology to Bcl-2 family
members, F1L inhibits the activation of both Bak and Bax by binding
to Bak and the BH3 only protein Bim (Campbell et al., 2010; Taylor
et al., 2006; Wasilenko et al., 2005). The crystal structure of F1L from
the vaccinia virus-modiﬁed strain Ankara indicated that despite lack
of apparent sequence homology to cellular Bcl-2 proteins, F1L adopts
a Bcl-2-like fold (Kvansakul et al., 2008).
Ectromelia virus (ECTV) is the causative agent of mousepox and a
member of the Orthopoxvirus family that is closely related to VACV
and variola virus (Esteban and Buller, 2005). Being a member of the
Orthopoxvirus family, we suspected that ECTV also encoded an
inhibitor of apoptosis. Using genome analysis we identiﬁed
EVM025. Based on the C-terminal homology between EVM025 and
F1L, we hypothesized that EVM025 could inhibit apoptosis. Here we
report that human and mouse cells infected with ECTV are resistant
to staurosporine (STS) and UV-induced apoptosis. We generated a
recombinant ECTV lacking a functional EVM025 that replicated
efﬁciently in tissue culture but was unable to protect against
staurosporine-induced apoptosis. Expression of EVM025 is critical
for maintaining the mitochondrial membrane potential and inhibit-
ing apoptosis during viral infection. EVM025 localizes to the mito-
chondria through the C-terminal transmembrane domain and
prevents Bak activation. EVM025 prevents Bax activation by seques-
tering the BH3-only protein Bim. Collectively, our data suggest that
the ECTV protein EVM025 is a inhibitor of the intrinsic apoptosis
pathway, which functions together with other viral anti-apoptotic
proteins to prolong the life of an infected cell.
Results
Ectromelia virus infection inhibits apoptosis
Viruses have evolved a number of strategies to inhibit the
cellular apoptosis pathway for continued survival in a host. ECTV
Fig. 1. ECTV infection inhibits apoptosis. (A) Jurkat cells were either mock-infected (a, b), infected with VACVcop (c, d) or infected with ECTV (e, f) at an MOI of 5. Jurkat cells
overexpressing Bcl-2 were also mock-infected (g, h). After 6 h of infection cells were either treated with 2 mM STS for 120min to induce apoptosis (b, d, e, h) or mock-treated (a, c, e, g).
(B) MEF cells were either mock-infected (a, b), infected with VACVCop (c, d) or ECTV (e, f) at an MOI of 5. MEFBak/Bax/ cells were mock-infected (g, h). Six hours post-infection
cells were treated with 3 mM STS for 120 min to induce apoptosis. Apoptosis was assessed by TUNEL ﬂuorescence. Untreated controls showed low levels of TUNEL ﬂuorescence, while
mock-infected cells exposed to Staurosporine (STS) were TUNEL positive due to DNA fragmentation. Data are representative of at least three independent experiments.
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encodes a known anti-apoptotic protein, CrmA, that inhibits
caspase-8 activation following treatment with TNFα or FasL, but
CrmA is unable to inhibit the intrinsic apoptotic cascade (Dbaibo
et al., 1997; Miura et al., 1995). To determine whether ECTV has the
ability to inhibit the intrinsic apoptosis pathway, we treated
poxvirus-infected cells with STS (staturosporin), a compound that
exclusively triggers induction of the intrinsic apoptosis pathway.
Jurkat cells were either mock-infected (Fig. 1A, panels a and b),
infected with VACVCop (Fig. 1A, panels c and d), or ECTV (Fig. 1A,
panels e and f), and treated with 2 mM STS to induce apoptosis
(Fig. 1A, panels b, d, f, and h). Jurkat cells constitutively expressing
Bcl-2 were used as a positive control (Fig. 1A, panels g and h).
Mock-infected Jurkat cells, cells infected with VACVCop or ECTV,
and Jurkat-Bcl-2 were left untreated and displayed basal levels of
DNA fragmentation indicative of healthy cells (Fig. 1A, panels a, c,
e, and g). Jurkat cells treated with STS exhibited an increase in
ﬂuorescence that is characteristic of DNA fragmentation and
apoptosis (Fig. 1A, panel b). As previously observed, infection with
VACVCop inhibited STS induced DNA fragmentation (Fig. 1A panels
c and d). Additionally, cells infected with ECTV were also protected
against 2 mM STS induced apoptosis (Fig. 1A panel d and e).
Similarly, infection of human and mouse cell with ECTV inhibited
UV-induced apoptosis (data not shown). These data indicate that
ECTV is capable of inhibiting apoptosis in human cell lines.
Since mice are the natural hosts of ECTV, we assessed the
ability of ECTV to block cell death in murine cells (MEFs).
MEFBak /Bax / cells were used as a positive control since they
are resistant to mitochondrial apoptosis (Lindsten et al., 2000; Wei
et al., 2001). Untreated MEF and MEFBak /Bax / cells, as well
as MEF cells infected with VACVCop or ECTV were stained with
TUNEL, and displayed minimal basal levels of DNA fragmentation
(Fig. 1B, panels a, c, e, and g). MEF cells treated with STS exhibited
an increase in TUNEL ﬂuorescence characteristic of apoptosis
(Fig. 1B, panel b). Infection with either VACVCop or ECTV sig-
niﬁcantly inhibited STS-induced DNA fragmentation in MEF cells
(Fig. 1B). It was also observed that ECTV was able to inhibit
apoptosis triggered by UV (data not shown). These data suggest
that ECTV is capable of inhibiting apoptosis triggered by stimuli
that are speciﬁc to the intrinsic pathway in both human and
murine cell lines.
Intrinsic apoptosis is associated with the activation and clea-
vage of caspase-3 and poly-ADP ribose polymerase (PARP) (Duriez
and Shah, 1997). Caspase-3 is an initiator caspase, while PARP is a
nuclear protein that is cleaved upon caspase activation (Duriez and
Shah, 1997; Gobeil et al., 2001). To conﬁrm that ECTV can inhibit
the intrinsic apoptotic cascade, we monitored caspase-3 and PARP
activation following treatment with STS. Jurkat cells were mock-
infected, infected with VACVCop or ECTV, at an MOI of 5. Six hours
post-infection, cells were treated with 2 mM STS for 2, 4 and 6 h to
trigger apoptosis. Activated caspase-3 and cleaved PARP were
detected in mock-infected Jurkat cells treated with STS two hours
post-treatment, and PARP was completely processed into the
cleaved form following four hours of STS treatment (Fig. 2). In
contrast, infection of Jurkat cells, with either VACVCop or ECTV,
prevented the activation of caspase-3 and PARP following STS
treatment. These data suggest that ECTV infection can block
apoptosis somewhere upstream of caspase-3 activation.
ECTV encodes EVM025 a homologue of VACV F1L
VACV encodes F1L, an inhibitor of mitochondrial apoptosis
(Campbell et al., 2010; Stewart et al., 2005; Taylor et al., 2006;
Wasilenko et al., 2005), and orthologues of F1L are only found
within members of the Orthopoxviridae (Fig. 3). EVM025, the
ectromelia virus orthologue, is 95% identical to F1L, but encodes a
large N-terminal extension comprised of up to 30 copies of an eight
amino acid motif, “Asp-Asn-Gly-Ile-Val-Gln-Asp-Ile” (DNGIVQDI).
This eight amino acid motif is also present twenty-ﬁve times in
EVM025 from ECTV strain Naval, and so far is unique to EVM025 of
ectromelia virus as it is absent in other orthopoxvirus F1L ortholo-
gues, nor is it present in any other known cellular or viral proteins.
Intriguingly, variola virus (VARV) Garcia also contains a large
N-terminal extension, consisting of 36 aspartic acid-rich repeats
(DDI) that are absent in VARV Bangladesh, and the function of these
repeat regions is currently unknown. The C-terminal amino half of
EVM025 shares 95% sequence identity with VACV Cop F1L, although
there are multiple substitution mutations, as well as a single DI
insertion mutation (Fig. 3). Given the high degree of sequence
identity between F1L and EVM025, we hypothesized that EVM025
might also act as an anti-apoptotic protein to facilitate ECTV
pathogenesis.
EVM025 expression protects cells against intrinsic apoptosis
To further elucidate the anti-apoptotic mechanism of EVM025
and its importance in modulating the cellular apoptotic response
during virus infection, we generated two recombinant viruses; one
virus that is devoid of EVM025 (ECTVΔ025), and a double deletion
virus that is missing both EVM025 and CrmA (ECTVΔ025/ΔCrmA).
The genetic proﬁle and purity of the knockout and revertant virus
was conﬁrmed by PCR in MEF cells (Fig. 4).
To determine the contribution of EVM025 during virus infec-
tion, MEF cells were mock-infected or infected with ECTV,
ECTVΔ025, ECTVΔCrmA, ECTVΔ025/ΔCrmA and ECTVΔ025rev at
a MOI of 5. After 6 h of infection the cells were treated with 2 mM
STS for an additional 2 h to trigger apoptosis, and the mitochon-
drial membrane potential was monitored using TMRE staining
Fig. 2. ECTV protects cells from staurosporine-induced apoptosis. Jurkat cells were
mock-infected, infected with VACVCop, and ECTV at an MOI of 5. Six hours post-
infection cells were treated with 2 mM STS. Samples were collected at 2, 4, and 6 h
post-STS treatment and cells were lysed in 1% NP40 cell lysis buffer. Samples were
subjected to SDS-PAGE and immunoblotted for PARP and caspase 3 to assess
apoptosis. β-tubulin was used as a loading control and I3L as a control for infection.
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(Ehrenberg et al., 1988; Farkas et al., 1989). In the absence of STS
treatment, mock-infected cells retained TMRE in healthy respiring
mitochondria and demonstrated high levels of TMRE ﬂuorescence
(Fig. 5A, panel a). In contrast, mock-infected cells treated with STS
showed a clear loss of TMRE ﬂuorescence, indicative of the loss of
inner mitochondrial membrane potential and apoptosis (Fig. 5A,
panel a). MEF cells infected with ECTV were protected against the
loss of inner mitochondrial membrane potential following STS
treatment (Fig. 5A, panel b). Interestingly, loss of TMRE ﬂuores-
cence was observed in MEF cells infected with ECTVΔ025 and
subsequently treated with STS (Fig. 5A, panel c). Similar to ECTV,
MEF cells infected with ECTVΔCrmA and ECTVΔ025rev were
protected against loss of mitochondrial respiration upon STS
treatment. However, MEF cells infected with ECTVΔ025/ΔCrmA
were unable to maintain the inner mitochondrial membrane
potential. These data indicate that EVM025, and not CrmA, is
required for ECTV to inhibit STS-induced apoptosis.
Following loss of mitochondrial membrane potential, cyto-
chrome c is released which triggers the activation of the apopto-
some leading to intrinsic apoptosis (Willis and Adams, 2005). We
next assessed the role of EVM025 in preventing cytochrome c
release during virus infection. Jurkat cells were infected with
ECTV, ECTVΔ025, ECTVΔCrmA, and ECTVΔ025/ΔCrmA, treated
with 2 mM STS and analyzed at 2, 4, and 6 h post-stimulation
(Fig. 5B) for cytochrome c release analysis by western blot. While
cytochrome c was rapidly released from mitochondria into the
cytosol in mock-infected cells treated with STS, cytochrome c was
retained in the mitochondria of ECTV-infected Jurkat cells, indi-
cating that ECTV protected cells from STS-induced cytochrome c
release. Similar protection was also observed in Jurkat cells
Fig. 3. Sequence alignment of EVM025 and its orthologs. Sequence alignment of the following orthologs: VACVCop F1L (AAA48014), VARV Bangladesh C5L (AAA60773),
VARV Garcia E1L (CAB54625), CPXV Brighton Red CPXV048 (NP_619836.1), MPXV Zaire C7L (AAY97031), ECTV strain Naval EVM025 (VP0042282), and ECTV strain Moscow
EVM025 (NP_671543). Sequences alignments were generated using the ClustalW program with a BLOSUM32 matrix. The conserved BH (BH homology) domains and
transmembrane tail of the proteins are marked with the over-lines. The black shaded regions are amino acids conserved though all the proteins. The gray shaded regions are
amino acids conserved among most proteins.
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infected with ECTVΔCrmA. In contrast, cells infected with ECTVΔ025
or ECTVΔ025/ΔCrmA and treated with STS demonstrated abundant
cytosolic cytochrome c. Together these data suggest that EVM025 is
important in preserving the mitochondrial membrane integrity to
block apoptosis.
Jurkat cells were analyzed for STS-induced PARP cleavage after
infection with ECTV, ECTVΔ025, ECTVΔCrmA, and ECTVΔ025/ΔCrmA.
Mock-infected Jurkat cells rapidly processed full length PARP into the
cleaved form upon STS treatment. Four hours post-STS treatment full-
length PARP was completely converted into the 89 kDa cleaved form
(Fig. 5C). Infection was conﬁrmed using an antibody to the early ECTV
protein I3L, and β-tubulin was used as a loading control (Fig. 5C). As
expected, ECTV and ECTVΔCrmA protected against STS-induced PARP
cleavage. However, infection with ECTVΔ025 and ECTVΔ025/ΔCrmA
was unable to protect against STS-induced PARP cleavage.
In addition to assessing the ability of ECTV to block STS-induced
apoptosis, we also asked whether EVM025 was sufﬁcient to protect
against infection-induced cell death, as virus infection can induce
apoptosis. MEF cells were either mock-infected or infected with
ECTV, ECTVΔ025, ECTVΔCrmA, or ECTVΔ025/ΔCrmA. MEF cells
infected with ECTV and ECTVΔCrmA showed no change in the
amounts of full length PARP for 48 h post-infection. In contrast, MEF
cells infected with ECTVΔ025 or ECTVΔ025/ΔCrmA induced PARP
cleavage as early as 12 h post-infection, and by 36 h post-infection,
no full length PARP was detected in these infected cells. These data
indicate that EVM025 prevents the induction of apoptosis during
ECTV infection. This experiment highlights the importance of
EVM025 during in-vitro infection.
EVM025 is a tail-anchored protein that localizes to the mitochondria
The anti-apoptotic protein Bcl-2 possesses a C-terminal tail
anchor that targets proteins to the mitochondrial membrane
(Chipuk et al., 2010; Youle and Strasser, 2008). Sequence analysis
of EVM025 conﬁrmed the presence of a thirteen amino acid
hydrophobic domain ﬂanked by positively charged lysines at posi-
tions 436 and 450 in EVM025, suggesting that EVM025 localizes to
the mitochondria. To evaluate whether EVM025 localizes to the
mitochondria, HeLa cells were transfected with either pEGFP-C3,
pEGFP-EVM025, or pEGFP-EVM025(Δ438453), a mutant con-
struct that lacked the predicted transmembrane domain. Sixteen
hours post-transfection cells were stained with MitoTracker to
visualize the mitochondria (Fig. 6). Cells transfected with the
control vector pEGFP showed a diffuse pattern of GFP expression
(Fig. 6, panel e). In contrast, cells transfected with pEGFP-EVM025
displayed a reticular ﬂuorescence pattern that co-localized with
mitochondrial staining (Fig. 6, panel g). When the predicted
transmembrane domain was removed (EVM025(Δ438453)), a
diffuse staining pattern similar to the control vector was observed
(Fig. 6, panel j). These data suggest that like Bcl-2, EVM025 is a
mitochondria-localized protein, and this localization is dependent
on the C-terminal transmembrane domain.
EVM025 interacts with Bak to prevent Bak activation
The activation of Bak is an essential step in the intrinsic
apoptotic pathway that precedes the release of cytochrome c from
the mitochondria (Antignani and Youle, 2006; Westphal et al.,
2011). Following an apoptotic stimulus, Bak undergoes a conforma-
tional change that results in the exposure of the N-terminus,
resulting in destabilization of the outer mitochondrial membrane
potential, loss of mitochondrial membrane integrity, and the release
of molecules like cytochrome c and SMAC/Diablo (Chipuk et al.,
2010). To determine whether EVM025 could prevent the conforma-
tional change of Bak, we assessed Bak activation following apoptotic
stimulation. Jurkat cells were either mock-infected or infected with
ECTV, ECTVΔCrmA, ECTVΔ025, or ECTVΔ025/ΔCrmA, and activa-
tion of Bak and exposure of the Bak N-terminus was induced by STS
treatment (Fig. 7A). Exposure of the Bak N-terminus during Bak
activation was detected with a conformation-speciﬁc anti-Bak AB-1
antibody and analyzed by ﬂow cytometry. As expected, uninfected
cells treated with STS exhibited a signiﬁcant increase in ﬂuores-
cence intensity (Fig. 7A, panel a), indicating the conformational
change and activation of in Bak. Infection of Jurkat cells with ECTV
Fig. 4. Characterization of the recombinant ECTV devoid of EVM025. (A) Schematic diagram of the strategy employed for the generation of ECTVΔ025 virus. The binding site
of the EVM025 sequencing primers as also indicated in the ﬁgure. (B)Viral DNA was extracted from BGMK cells infected with ECTV, ECTVΔEVM025, ECTVΔCrmA,
ECTVΔEVM025/ΔCrmA, and ECTVΔEVM025rev. Successful deletion of EVM025 was conﬁrmed by PCR using EVM025-forward primer and EVM025-reverse primer.
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or ECTVΔCrmA, on the other hand, inhibited the exposure of the
Bak N-terminus following STS treatment (Fig. 7A, panel b). Infection
with ECTVΔ025 and ECTVΔ025/ΔCrmA did not inhibit STS-induced
Bak activation (Fig. 7A, panels c and d), suggesting that EVM025 is
necessary to inhibit the activation of Bak in infected Jurkat cells. We
next determined if EVM025 could interact with the pro-apoptotic
molecule Bak. BMK cells were transfected with pEGFP, pEGFP-Bcl-2,
or pEGFP-EVM025. Cells were lysed in 2% CHAPS, a detergent
known to preserve the conformational integrity of the Bcl-2 family
members (Yao et al., 2014). Immuno-complexes were precipitated
using a GFP antibody and detected using anti-Bak antibody (Fig. 7B).
Interestingly, EGFP-EVM025 associated with endogenous Bak, while
no Bak co-immunoprecipitation was seen with GFP alone. As
expected, pEGFP-Bcl-2 also co-precipitated Bak, as has been demon-
strated previously. Overall, our data suggests that EVM025 can asso-
ciate with endogenous Bak.
Next, we asked whether EVM025 could inhibit the induction of
apoptosis following Bak over-expression. Ectopic expression of Bak
saturates the mitochondrial membrane resulting in the activation of
the apoptotic cascade (Chittenden et al., 1995). HeLa cells were co-
transfected with HA-Bak, along with pEGFP, pEGFP-EVM025, or
pEGFP-Bcl-2. Cells transfected with empty EGFP underwent a loss
of TMRE ﬂuorescence following over expression of HA-Bak (Fig. 7C).
Cells transfected with EGFP-EVM025, on the other hand, were
protected from Bak-induced apoptosis (Fig. 7C). Similar results were
observed in cells transfected with EGFP-Bcl-2 (Fig. 7C), a protein
known to inhibit Bak-induced apoptosis. Overall, these data indicate
that EVM025 directly interacts with Bak and this interaction prevents
the activation of Bak-induced apoptosis.
EVM025 prevents apoptosis induced by Bax
The other key pro-apoptotic mitochondrial regulator, Bax, exists in
an inactive form in the cytoplasm and undergoes a conformational
change in response to an apoptotic stimulus, resulting in the exposure
of its N-terminus and localization to the mitochondria (Oltvai et al.,
1993). Activated Bax undergoes homo-oligomerization facilitating
mitochondrial damage and ultimately results in the release of cyto-
chrome c (Annis et al., 2005). To determine if EVM025 could inhibit
Bax activation, we used ﬂow cytometry to monitor the conformational
change of activated Bax. Jurkat cells were either mock-infected, or
infected with ECTV, ECTVΔCrmA, ECTVΔ025, or ECTVΔ025/ΔCrmA.
Six hours post-infection, the activation of Bax was induced by STS
treatment, and the conformational change in Bax was detected by
staining with anti-Bax6A7, an antibody that recognizes the Bax
N-terminus, a domain only exposed during apoptosis. Upon STS treat-
ment of uninfected Jurkat cells, a signiﬁcant increase in anti-Bax 6A7
ﬂuorescence was seen as compared to untreated cells, indicating that
Bax was activated and underwent a conformational change exposing
its N-terminus (Fig. 8A, panel a). Conversely, cells infected with ECTV
(Fig. 8A, panel b) or ECTVΔCrmA (Fig. 8A, panel c) completely
inhibited the activation of Bax upon STS treatment. In contrast, cells
infected with ECTVΔ025 (Fig. 8A, panel d) or ECTVΔ025/ΔCrmA
(Fig. 8A, panel e) were not protected from STS-induced Bax activation,
suggesting that EVM025 can inhibit Bax activation.
Next we determined if EVM025 could inhibit apoptosis induced
by Bax over-expression. HeLa cells were co-transfected with HA-Bax,
and pEGFP, pEGFP-Bcl-2, or pEGFP-EVM025, and apoptosis was
quantiﬁed in transfected cells by measuring mitochondrial mem-
brane potantial TMRE (Fig. 8B). Overexpression of Bax resulted in the
artiﬁcial activation of Bax and subsequent loss of the mitochondrial
membrane potential in 45% of EGFP-transfected cells. Interestingly,
transfection of EGFP-EVM025 protected the cells against Bax-induced
apoptosis. Similarly, transfection of EGFP-Bcl-2 signiﬁcantly inhibited
apoptosis induced by Bax over-expression, as expected. We failed to
detect any interaction between EVM025 and Bax (data not shown).
The lack of interaction between Bax and EVM025 suggests that
EVM025 functions by interacting with a BH3-only protein upstream
of Bax to prevent its activation.
EVM025 inhibits Bim-induced apoptosis
EVM025 expression inhibited Bax activation, but no direct
interaction between EVM025 and Bax was detected, suggesting that
EVM025 may function upstream of Bax. The BH3-only protein Bim
acts as a direct upstream activator of Bax, and is activated during
cellular stress such as virus infection (Bouillet et al., 1999; Connor et
al., 1998). To examine the possible interaction between EVM025 and
BimL, HeLa cells were co-transfected with FLAG-BimL and either
EGFP, EGFP-Bcl2, or EGFP-EVM025, and immunoprecipitated with
anti-GFP (Fig. 9A). Western blotting with anti-Bim demonstrated
that both EGFP-EVM025 and EGFP-Bcl-2 co-precipitated with BimL,
whereas no interaction was observed with EGFP. These data indicate
that EVM025 can associate with BimL.
We next sought to determine if EVM025 could prevent apoptosis
induced by BimL over-expression. HeLa cells were co-transfected
with Flag-BimL and pEGFP, pEGFP-Bcl-2 or pEGFP-EVM025 for 12 h,
and apoptosis was assessed by staining with TMRE and ﬂow
cytometry (Fig. 9B). In cells transfected with pEGFP, and Flag-BimL,
approximately 40% of the cells showed a loss of TMRE staining.
Conversely, only 3% of cells showed a loss of TMRE when Flag-BimL
was co-expressed with EGFP-Bcl-2, a cellular antagonist of BimL
protein. Similar results were observed in cells transfected with BimL
and EVM025, where only 7% of the transfected population showed a
loss of TMRE staining. These results indicate that EVM025 interacts
with the BH3 only protein BimL and prevents BimL-induced apop-
tosis. Thus it is likely that EVM025 inhibits the activation of the pro-
apoptotic protein Bax by interacting and inhibiting the activity of its
upstream regulator Bim.
Discussion
Apoptosis is a critical tool used by the cell to block virus
replication, and it is not surprising that many viruses have evolved
strategies to overcome or delay cell death (Barry et al., 2004;
Benedict et al., 2002; Galluzzi et al., 2008). Human and murine
cytomegaloviruses inhibit the apoptotic pathway through a unique
apoptosis inhibitor, vMIA (Norris and Youle, 2008). The gammaher-
pesviruses Kaposi's sarcoma-associated herpesvirus (KSHV), Epstein
Barr virus (EBV), and murine gammaherpesvirus-68 (MHV-68)
encode viral homologs of the cellular anti-apoptotic protein Bcl-2
(v-Bcl-2) to inhibit the intrinsic apoptosis pathway (Barry et al., 2004;
Benedict et al., 2002; Cuconati and White, 2002; Galluzzi et al., 2008;
Kepp et al., 2009; Norris and Youle, 2008; Pogo et al., 2003; Teodoro
and Branton, 1997). Other viruses such as African swine fever virus
(ASFV) and Adenovirus also encode vBcl-2 homologs that inhibit
apoptosis. Poxviruses are renowned for their ability to manipulate
the apoptotic pathway, and they encode a variety of distinct proteins
that interfere with the Bcl-2 family of proteins (Cuconati and White,
2002; Taylor and Barry, 2006). Avipoxviruses encode obvious cellular
Bcl-2 homologs, while several other members of the poxvirus family
encode anti-apoptotic proteins that lack sequence similarity to
cellular Bcl-2 proteins (Banadyga et al., 2007; Tulman et al., 2004).
Previous work performed in our laboratory led to the identiﬁcation of
F1L in vaccinia virus (Wasilenko et al., 2003). VACV F1L consists of
divergent Bcl-2 homology domains and replaces cellular anti-
apoptotic proteins, Mcl-1 and Bcl-2, during infection to prevent
apoptosis (Campbell et al., 2010).
Ectromelia virus (ECTV), more commonly known as mousepox, is
a member of the Orthopoxviridae that was ﬁrst described in 1930
(Esteban and Buller, 2005). A majority of our understanding
N. Mehta et al. / Virology 475 (2015) 74–87 79
regarding orthopoxviruses has come through the use of VACV,
whose natural host is unknown. ECTV, however, is a natural
pathogen of mice. Understanding the virulence of ECTV will help
improve our understanding of poxvirus infection. To date, no work
has investigated the role of EVM025 in apoptotic inhibition during
ectromelia virus infection. Our data conﬁrm that ECTV encodes a
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functional mitochondrial inhibitor of apoptosis, EVM025, which
inhibits cell death induced at the mitochondria via the intrinsic
pathway. Both human and murine cells infected with wild-type
ECTV, but not ECTVΔ025 viruses, were inhibited from apoptosis
induced by multiple stimuli. We also found that EVM025 blocks
apoptosis at the mitochondria, much like VACV F1L poxviral
inhibitors of apoptosis, including M11L and F1L, are localized at
the mitochondria (Everett et al., 2000; Stewart et al., 2005). Wewere
able to establish that similar to F1L, EVM025 also localizes to the
mitochondria via a C-terminal hydrophobic tail (Fig. 6).
Many of the poxviral mitochondrial anti-apoptotic proteins, such
as M11L, F1L, FPV039 and DPV022, are believed to function
primarily by inhibiting the activation of Bak and Bax (Banadyga
et al., 2007, 2011, 2009; Everett et al., 2002; Taylor et al., 2006;
Wasilenko et al., 2005). Our data suggests that the expression of
EVM025 was similarly sufﬁcient to prevent the activation of Bak
and Bax (Figs. 7 and 8). EVM025 was able to interact directly with
endogenous Bak, but not with Bax. This is similar to results
previously observed with F1L. In contrast, M11L, DPV022, and
FPV039 are able to interact with both Bak and Bax to prevent their
activation during virus infection. Since EVM025 inhibits the activa-
tion of Bax in the absence of detectable interaction, we hypothe-
sized that EVM025 may function by interacting with and inhibiting
BH3-only proteins that act upstream of Bax activation. One such
upstream activator of Bax is the BH3-only protein Bim. Bim exists as
three isoforms, BimS, BimL and BimEL, and is able to trigger
apoptosis in response to various stimuli. EVM025 expression
signiﬁcantly inhibited BimL-induced loss of mitochondria mem-
brane potential, a hallmark of apoptotic cells, and EVM025 was also
seen to weakly interact with ectopically expressed BimL (Fig. 9). It is
interesting to note that previous work done on F1L demonstrates
that F1L is able to bind to BimL strongly. This is not the case with
EVM025. Addition work needs to be done to determine the ability
of EVM025 to interfere with function of other BH3-only proteins.
The orthopoxviral proteins F1L and EVM025 appear to function
differently from the other poxviral proteins (M11L, FPV039) despite
their similar anti-apoptotic phenotype suggesting different a differ-
ent biochemical mechanism (Banadyga et al., 2007, 2009).
Sequence analysis of genomes of orthopoxviridae revealed that
orthologues of F1L were found in multiple members of the family
(Fig. 3). Our analysis showed that F1L orthologs from VARV Garcia,
ECTV Moscow, and ECTV Naval have a distinct repetitive sequence at
the amino terminus of the protein. The repetitive sequence is absent in
other members of the orthopoxviridae family. EVM025 consists of a
long N-terminal repeat region consisting of an eight amino acid motif
‘DNGIVQDI’ repeated 30 times. Similar to this, VARV Garcia contains
multiple ‘DDI’ repeats at the N-terminus. These repeat regions share no
sequence homology with any known cellular or viral proteins, and
display no similarity to predicted secondary structure. Although the
functional importance of these repeated regions remains unknown, the
repeat regions are absent in VACV Copenhagen, VARV Bangladesh,
MPXV Zaire, and CPVX Brighton Red, suggesting that they were lost or
gained during evolution. Additional studies are required to improve our
understanding of the functional and evolutionary importance of these
regions. Despite the variability present at the N-terminal region of the
F1L orthologues, F1L and EVM025 share 95% sequence homology at the
C-termini (Fig. 3). Based on the C-terminal similarity it is likely that
ECTV EVM025 will fold in a manner similar to F1L. Previous work has
shown that F1L, despite lacking obvious sequence similarity with
cellular Bcl-2, folds in a manner similar to cellular Bcl-2 protein
(Campbell et al., 2010; Kvansakul et al., 2008). The predicted divergent
BH domains of F1L are highly conserved between EVM025 and other
orthologues of the orthopoxviridae family. Poxviruses have recently
been shown to encode a variety of proteins that adopt a Bcl-2-like
conformation (Gonzalez and Esteban, 2010; Graham et al., 2008). A52R
and B14R both share limited sequence similarity with cellular Bcl-2
proteins but fold like the Bcl-2 proteins. Despite their secondary
structure, A52R and B14R are involved in inhibiting the NF-κB pathway
but not apoptosis (Graham et al., 2008). Several other vaccinia viral
proteins, such as A46R, K7R, N1L and C1L, have all been reported to
possess Bcl-2-like folds, and thus could be grouped within the same
protein family (DiPerna et al., 2004; Gonzalez and Esteban, 2010;
Graham et al., 2008). Of these proteins, however, only N1L has been
shown to have any ability to inhibit apoptosis (Cooray et al., 2007).
Other studies has shown that N1L is involved in the modulation of
NFκB pathway and not apoptosis (DiPerna et al., 2004). The role of
Fig. 5. EVM025 ORF is required to inhibit apoptosis during infection. (A) EVM025 protects cells from STS-induced loss of the outer mitochondrial membrane potential. Jurkat
cells were mock-infected (a), infected with ECTV (b), ECTVΔ025 (c), ECTVΔCrmA (d), ECTVΔ025/ΔCrmA (e), or ECTVΔ025rev (f) at an MOI of 5. Six hours post-infection cells
were treated with 2 mM staurosporine for 90 mins or mock-treated and stained with 2 mM of TMRE. Untreated cells, (shaded histogram); staurosporine treated cells, open
histogram. Data are representative of three independent experiments. Apoptosis was assessed by TMRE ﬂuorescence, which measures loss of the inner mitochondrial
membrane potential. (B) EVM025 expression inhibits STS induced cytochrome c release. Jurkat cells were infected with ECTV, ECTVΔ025, ECTVΔCrmA, and
ECTVΔ025ΔCrmA at an MOI of 5 for 6 h. Six hours post-infection, the samples were treated with 2 mM STS. Cells were collected at 2, 4, and 6 h post-STS treatment. The
cytosolic fraction was obtained by permeabilization using digitonin. The pellet fraction was resuspended in 0.1% Triton lysis buffer. Both the pellet and the supernatant
fraction were immunoblotted with anti-cytochrome c. (C) EVM025 expression inhibits STS induced apoptosis. Jurkat cells were mock-infected, infected with ECTV,
ECTVΔCrmA, ECTVΔ025, or ECTVΔ025/ΔCrmA at an MOI of 5. Six hours post-infection, samples were treated with 2 mM STS. Cells were collected at 2, 4, and 6 h post STS
treatment, and cells were lysed in SDS sample buffer containing 8 M urea. Samples were subjected to SDS-PAGE and immunoblotted for PARP to determine the trigger of
apoptosis. β-tubulin was used as a loading control and I3L as a control of infection. (D) EVM025 inhibits virus induced PARP cleavage. MEF cells were mock-infected or
infected with ECTV, ECTVΔCrmA, ECTVΔ025, or ECTVΔ025/ΔCrmA at an MOI of 5. Cells were collected 12, 24, 36 and 48 h post-infection, and lysed in SDS-PAGE sample
buffer containing 8 M urea. Samples were subjected to SDS-PAGE and immunoblotted for PARP to determine virus induced apoptosis. β-tubulin was used as a loading control
and I3L as a control for infection.
Fig. 6. EVM025 localizes to the mitochondria. MEF cells were mock-infected
transiently transfected with pEGFP, pEGFP-EVM025(1-456) or pEGFP-EVM025
(Δ438453). Fourteen hours post-transfection the mitochondria were stained with
15 ng/ml of MitoTracker Red CMXRos (Invitrogen Corp.). The cells were observed
under a spinning disc confocal microscope.
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Fig. 7. EVM025 expression inhibits Bak activation. (A) EVM025 expression inhibits Bak activation. Jurkat cells were mock-infected (a), infected with ECTV (b), ECTVΔCrmA
(c), ECTVΔ025 (e) or ECTVΔ025/ΔCrmA (f) at an MOI of 5 for 4 h, followed by treatment with 0.25 mM STS for 2 h to induce apoptosis. Exposure of the N-terminus of Bak was
monitored by ﬂow cytometry using a conformation-speciﬁc N-terminal Bak Ab-1 antibody. Untreated cells, (shaded histogram); STS treated cells (open histogram). Data are
representative of at least three independent experiments. (B) EVM025 interacts with endogenous Bak. BMK cells were transfected with pEGFP, pEGFP-Bcl-2, or pEGFP-
EVM025. Cells were lysed in CHAPs buffer and cellular lysates were immunoprecipitated (IP) with anti-GFP. The immuno-precipitates were immunoblotted with anti-Bak NT
or anti-GFP antibody. Cell lysates were immunoblotted with anti-EGFP to check the expression of the EGFP constructs, and anti-Bak NT to determine the levels of
endogenous Bak. (C) EVM025 expression inhibits Bak induced apoptosis. HeLa cells were co-transfected with pEGFP, pEGFP-Bcl-2, and pEGFP-EVM025 and pcDNA-Flag-Bak
for 16 h stained with 50 nM TMRE to label mitochondria, and apoptosis was analyzed in EGFP-positive cells using two-color ﬂow cytometry. Assays were performed in
triplicate and were quantiﬁed as the mean percentage of EGFP-positive cells (7S.D.) demonstrating a loss of TMRE uptake. Flag-Bax expression levels from transfected cells
were analyzed by Western blotting with an anti-Flag antibody. nnnPo0.001.
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these or any other putative anti-apoptotic proteins remains to be seen.
Our data, however, conﬁrm the hypothesis that EVM025 is the
predominant anti-apoptotic inhibitor, as EVM025 knock-out viruses
are completely unable to block apoptosis induced by multiple intrinsic
pro-apoptotic stimuli (Figs. 4, 7 and 8), thereby casting some doubt on
the ability of other ectromelia virus proteins to also contribute to the
inhibition of apoptosis. We hope that the work done in this article
helps setup the foundation to address the importance of EVM025 in a
mouse model.
EVM025 is a potent anti-apoptotic poxviral protein, similar to
F1L. EVM025 has a distinct N-terminal end with an unknown
function. EVM025 shares little similarity to cellular Bcl-2 proteins,
yet effectively inhibits apoptosis. It is evident from this study that
EVM025 is evolutionarily related to F1L, at some point in the
evolution the N-terminus of EVM025 was lost, and subtle differ-
ences arose. But the basic function still remains to inhibit apop-
tosis to achieve the ﬁnal goal of keeping the infected cell alive.
Materials and methods
Cells and viruses
HeLa cells were obtained from the American Type Culture
Collection (ATCC), Human embryonic kidney 293T (HEK293T),
Baby mouse kidney (BMK) and CV-1 cells were grown in
Dulbecco's Modiﬁed Eagle's Medium (DMEM) (Life Technologies)
supplemented with 10% fetal bovine serum (FBS) (Life Technol-
ogies), 2 mM L-glutamine (Life Technologies), 50 U/ml penicillin
(Life Technologies), and 50 mg/ml streptomycin (Life Technolo-
gies). Wild type and Bak/Bax / deﬁcient mouse embryonic
ﬁbroblasts were provided by Dr. S. Korsmeyer and cultured in
DMEM containing 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin,
50 mg/ml streptomycin and 100 mM MEM non-essential amino
acid solution (Life Technologies). Baby green monkey kidney
(BGMK) cells were obtained from ATCC and maintained in DMEM
containing 10% newborn calf serum (NCS) (Life Technologies),
2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomy-
cin. Jurkat cells were maintained in Roswell Park Memorial
Institute 1640 medium (RPMI) (Life Technologies) supplemented
with 10% FBS, 50 U/ml penicillin, 50 mg/ml streptomycin, and
100 mM β-mercaptoethanol (Bioshop Canada Inc.). Jurkat cells
stably expressing Bcl-2 were generated as previously described
(Heibein et al., 2000). Vaccinia virus (VACV) strain Copenhagen
(VACVCop) was provided by Dr. G. McFadden (University of
Florida, Gainesville, Florida). Ectromelia virus strain Moscow
(ECTV), and ECTVΔCrmA were provided by Dr. M. Buller (St.
Louis University, St. Louis, Missouri). All viruses were propagated
in BGMK cells and puriﬁed as previously described (Stuart et al.,
1991).
Fig. 8. EVM025 expression inhibits Bax activation. (A) EVM025 expression inhibits Bax activation. Jurkat cells were mock-infected (a), infected with ECTV (b), ECTVΔCrmA
(c), ECTVΔ025 (d) or ECTVΔ025/ΔCrmA (e) at an MOI of 5 for 4 h, followed by treatment with 0.25 mM STS for 2 h to induce apoptosis. Exposure of the N-terminus of Bax was
monitored by ﬂow cytometry using a conformation-speciﬁc N-terminal Bax 6A7 antibody. Untreated cells, (shaded histogram); STS treated cells (open histogram). Data is the
representative of at least three independent experiments. (B) EVM025 expression inhibits Bax induced apoptosis. HeLa cells were co-transfected with pEGFP, pEGFP-Bcl-2,
and pEGFP-EVM025 and pcDNA-Flag-Bax for 16 h stained with 50 nM TMRE to label mitochondria, and apoptosis was analyzed in EGFP-positive cells using two-color ﬂow
cytometry. Assays were performed in triplicate and were quantiﬁed as the mean percentage of EGFP-positive cells (7S.D.) demonstrating a loss of TMRE uptake. Transfected
Flag-Bax expression levels from transfected cells were analyzed by Western blotting with anti-Flag antibody. ***Po0.001.
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Generation of recombinant viruses
To generate an ECTV virus lacking EVM025, we cloned enhanced
green ﬂuorescent protein (EGFP) under the control of a synthetic
poxviral early/late promoter (E/L) with ﬂanking BglII sites. The
poxviral early/late promoter (pE/L) and EGFP was ampliﬁed from
pSC66-EGFP using primers E/LSynFor and EGFP (BglII) and the ﬁnal
product was cloned into pGEM-T (Promega). To generate the
EVM025 knockout cassette, a region of EVM025 containing 158 base
pairs upstream of EVM025 and the ﬁrst 45 base pairs of the 50 end of
EVM025 was ampliﬁed using the forward primer EVM025koF1 50-
AGAATAGCTCAGCTAATCTAT-30 and reverse primer EVM025koR1 50-
AATGCAGATCTGGATCTACGATATTATACATAAACATCGA-30. The down-
stream region consisting of the last 159 base pairs of EVM025 was
ampliﬁed using the forward primer EVM025koF2 50-GATCCA-
GATCTGCATTTCGCATACTATATGCGATGAT-30 and reverse primer
EVM025koR2 50-TGGATCCTTATCATATCATGTATTTGAG-30. EVM025-
koR1 and EVM025koF2 both contain an overhanging linker region
that encodes a BglII restriction site. The PCR products were included
in an overlapping PCR reaction to obtain a continuous fragment of
the upstream and downstream fragments of EVM025 separated by
the BglII restriction site. The 347 base pair fragment was cloned into
a pGEMT vector (Life Technologies). An EGFP cassette under the
control of a synthetic early/late poxviral promoter was inserted
using the BglII restriction site between the upstream and down-
stream EVM025 fragments (pGEMT-EVM025/b-EGFP). This effec-
tively encodes a disrupted non-functional version of EVM025. ECTV
wild type was used to generate ECTVΔ025 by homologous recom-
bination lacking approximately 80% of the EVM025 ORF.
In order to generate a version of ECTV deﬁcient in CrmA and
EVM025, we generated an EVM025 knockout using the vector
described above in the background strain ECTVΔCrmA. BGMK
cells (1106) were infected with ECTV at an MOI of 0.05 and
transfected with pGEMT-EVM025/d-EGFP using Lipofectamine
2000. Recombinant viruses were selected by EGFP ﬂuorescence
and plaque puriﬁed. The disrupted EVM025 open reading frame
was conﬁrmed by PCR and sequencing using the primers EVM025-
forward-ATGGACAATAGTATTTTGTCG and EVM025-reverse-ATCA-
TATCATGTATTTGAG.
ECTVΔ025 was used as the backbone to generate the EVM025
revertant virus (ECTVΔ025rev). The wildtype EVM025 gene was
ampliﬁed using the forward primer EVM025koF1 50-AGAATAGCT-
CAGCTAATCTAT-30 and the reverse primer EVM025koR2 50-TGGA-
TCCTTATCATATCATGTATTTGAG-30. BGMK cells (1106) were
infected with ECTV at an MOI of 0.05 and transfected with 10 mg
ampliﬁed PCR product using Lipofectamine 2000 (Life Technolo-
gies). Recombinant viruses were selected by picking white pla-
ques, and the presence of the wild-type EVM025 open reading
frame was conﬁrmed by PCR and sequencing.
Sequence alignments
The following sequences were used: VACVCop F1L (AAA48014),
VARV Bangladesh C5L (AAA60773), VARV Garcia E1L (CAB54625),
MPXV Zaire C7L (AAY97031), CPXV Brighton Red CPXV048
(NP_619836.1), ECTV strain Moscow EVM025 (NP_671543). Clus-
talW using the BLOSUM32 matrix was used to perform the
multiple alignments (Larkin et al., 2007).
PARP cleavage
To study poly-ADP ribose polymerase (PARP) cleavage, Jurkat
cells (1106) were mock-infected or infected with VACVCop,
ECTV, ECTVΔCrmA, ECTVΔ025, and ECTVΔ025/ΔCrmA at an MOI
of 5. Six hours post-infection Jurkat cells were treated with 2 mM
staurosporine (STS) (Sigma-Aldrich) and harvested six hours post-
STS treatment. Similarly, MEF cells (1106) were infected with
ECTV, ECTVΔCrmA, ECTVΔEVM025, and ECTVΔ025/ΔCrmA at an
MOI of 5 and harvested at 8, 12, 24, and 48 h post-infection. Cells
were lysed in SDS-PAGE sample buffer containing 8 M urea.
Fig. 9. EVM025 interacts with BimL and inhibts the apoptosis induced by BimL overexpression. (A) EVM025 interacts with BimL. HeLa cells were transfected with pEGFP,
pEGFP-Bcl-2, and pEGFP-EVM025 and pcDNA-Flag-BimL for 14 h. The cells were lysed in 2% CHAPS buffer, lysates were immunoprecipitated (IP) with anti-GFP (goat)
antibody and subjected to western blotting with anti-GFP or anti-Flag antibody to detect the interaction. Whole cell lysates were subjected to western blotting with the anti-
GFP or anti-Flag antibody to detect the expression levels of the transfected protiens. (B) EVM025 expression inhibits BimL overexpression induced apoptosis. HeLa cells were
co-transfected with pEGFP, pEGFP-Bcl-2, and pEGFP-EVM025 and pcDNA-Flag-BimL for 16 h. Transfected cells were stained with 50 nM TMRE to label mitochondria, and
apoptosis was analyzed in EGFP-positive cells using two-color ﬂow cytometry. Assays were performed in triplicate and were quantiﬁed as the mean percentage of EGFP-
positive cells (7S.D.) demonstrating a loss of TMRE uptake. Flag-Bax expression levels from transfected cells were analyzed by Western blotting with anti-Flag antibody.
nnnPo0.001.
N. Mehta et al. / Virology 475 (2015) 74–8784
Samples were subjected to SDS-PAGE and immunoblotted with
anti-PARP (BD PharMingen), anti-β-tubulin (EMC Bioscience), and
anti-I3L, kindly provided by Dr. D. Evans (University of Alberta,
Edmonton, Alberta).
Cytochrome c release
Jurkat cells (1106) were either mock-infected or infected
with VACVCop or ECTV at an MOI of 5. Six hours post-infection the
cells were treated with 2 mM STS and harvested at the indicated
time points. Cells were permeabilized in lysis buffer containing
75 nM NaCl, 1 mM NaH2PO4, 250 mM sucrose, and 190 mg/ml of
digitonin (Sigma-Aldrich). Lysates were incubated on ice for
10 min. Mitochondrial and cytoplasmic fraction were separated
by centrifugation for 10 min. The mitochondrial pellet was resus-
pended in Triton-X-100 lysis buffer containing 25 mM Tris pH8.0
and 0.1% Triton-X-100 (Fisher Scientiﬁc). Samples were subjected
to SDS-PAGE and blotted with anti-cytochrome c (BD PharMingen)
and anti-Bak NT (Upstate) antibodies.
Detection of DNA fragmentation by TUNEL
DNA fragmentation was assessed by using the terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling
method (TUNEL) (Roche Diagnostics). Jurkat cells (2106), Jurkat
Bcl-2 cells (2106), MEF cells (1106), and MEFBak /Bax /
cells (1106) were infected at an MOI of 5 for 6 h. Apoptosis was
stimulated using 2 mM STS for 2 h for Jurkat cells, or 3 h for MEF
cells. Cells were ﬁxed with 2% (w/v) paraformaldehyde in PBS for
10 min at room temperature and permeabilized with 0.1% Triton-
X-100 and 0.1% sodium citrate for 10 min on ice. Cells were stained
for 1 h at 37 1C with 25 U of terminal deoxynucleotidyltransferase
according to manufacturer's instructions (Roche Diagnostics). Cells
were washed with PBS containing 1% (v/v) FBS and analyzed on a
BD LSRFortessa ﬂow cytometer. In each experiment 30,000 cells
were analyzed. TUNEL positive cells were counted through the
FL-2 channel equipped with a 561 nm ﬁlter (586/15 nm band
pass), and data were analyzed with FlowJo (Tree Star, Inc.).
Mitochondrial membrane potential
Changes in mitochondrial membrane potential were assessed
by staining Jurkat cells with tetramethylrhodamine ethyl ester
(TMRE) (Life Technologies). MEF cells (1106) were either mock-
infected or infected with VACVCop, ECTV, ECTVΔ025, ECTVΔCrmA,
ECTVΔ025/ΔCrmA, or ECTVΔ025rev at an MOI of 5. After 6 h of
infection, the cells were treated with 2 mM STS for 2 h. MEF cells
were stained with 0.3 mM TMRE for 30 min at 37 1C. Cells were
washed with PBS containing 1% (v/v) FBS and analyzed using a BD
LSRFortessa ﬂow cytometer. TMRE positive cells were measured
using the FL-2 channel equipped with a 586/15 nm ﬁlter and data
were analyzed with FlowJo (Tree Star, Inc.).
HeLa cells (1106) were transfected with EGFP, EGFP-Bcl-2,
and EGFP-EVM025, using Lipofectamine 2000 for 12 h, and apop-
tosis was induced by co-expressing 1 mg of HA-Bak, or HA-Bax for
12 h. TMRE positive cells were measured through the FL-2 channel
equipped with a 586/15 nm ﬁlter and GFP positive cells were
measured through the FITC channel equipped with 530/30 nm
ﬁlter. Data was acquired by counting 30,000 cells was performed
on a BD LSRFortessa. The percentage of cells undergoing mito-
chondrial dysfunction was determined by dividing the total
number of EGFP positive and TMRE negative cells by the total
number of EGFP positive cells. Standard deviations were deter-
mined from three independent experiments.
Bak and Bax activation
Jurkat cells (1106) were infected with ECTV, ECTVΔ025,
ECTVΔCrmA, ECTVΔ025/ΔCrmA, or ECTVΔ025rev at an MOI of
5 for 6 h. Following infection, Jurkat cells were treated with 0.25 mM
STS for 2 h and ﬁxed with 0.25% paraformaldehyde. Cells were
permeabilized using 500 mM digitonin and stained with 2 mg/ml Bak
AB-1 antibody (EMD Millipore) or 2 mg/ml of an isotype control
antibody speciﬁc for NK1.1 provided by Dr. K. Kane (University of
Alberta, Edmonton, Alberta). The cells were counter stained with a
Phycoerythrin-conjugated antibody (Jackson ImmunoResearch)
before analysis on a BD LSRFortessa ﬂow cytometer using the FL-2
channel equipped with a 586/15 nm ﬁlter. Data were analyzed using
FlowJo (TreeStar, Inc.).
Jurkat cells were intentioned ECTVΔ025, EVCTΔCrmA,
ECTVΔ025/ΔCrmA, or ECTVΔ025rev at a MOI of 5 for 8 h. Follow-
ing infection, the cells were treated with 2.5 mM STS for 2 h and
then ﬁxed with 0.25% paraformaldehyde. Cells were permeablized
using 500 mM digitonin and stained with 3 mg/ml Bax6A7 antibody
(BD PharMingen) or 2 mg/ml of an isotype control antibody speciﬁc
for NK1.1. Phycoerythrin-conjugated antibody was used to coun-
terstain cells before analysis on BD LSRFortessa using the FL-2
channel equipped with a 586/15 nm ﬁlter and 20,000 cells were
analyzed using FlowJo (TreeStar, Inc.).
Confocal microscopy
HeLa cells were transiently transfected with 2 mg of pEGFP
(empty vector control), EGFP-EVM025 and EGFP-EVM025
(Δ1255) for 14 h using Lipofectamine 2000 (Life Technologies).
The Mitochondria were labeled with 15 ng/ml of MitoTracker Red
CMXRos (Life Technologies). Live cells were examined using the
AIVI Spinning Disk Confocal at 489 nm to detect EGFP ﬂuorescence
and 543 nm to detect MitoTracker.
Immunoprecipitation
To detect an interaction between EVM025 and endogenous Bak,
BMK cells (5106) were transfected with 5 mg of pEGFP-C3
(Clontech Laboratory Inc.), pEGFP-Bcl-2, or pEGFP-EVM025 using
X-tremeGENE HP DNA reagent (Roche Diagnostics). Transfected
cells were lysed 16 h post-transfection in 2% CHAPS (Sigma-
Aldrich) containing 150 mM NaCl, 50 mM Tris pH8.0 and Complete
Protease Inhibitors (Roche Diagnostics). Cell lysates were immu-
noprecipitated with anti-goat GFP antibody kindly provided by
Dr. L. Berthiaume (University of Alberta, Edmonton, Alberta).
Immune complexes were isolated using protein A-Sepharose (GE
Healthcare). Isolated immune complexes were subjected to Wes-
tern blot analysis. To study the interaction of Bax and BimL with
EVM025, HeLa cells were transfected with 4 mg of pEGFP-C3,
pEGFP-Bcl-2, or pEGFP-EVM025 and 2 mg pcDNA3-HA-Bax or
pcDNA3-Flag-BimL using 5 ml of Lipofectamine 2000 (Life Tech-
onologies). Transfected cells were lysed 16 h post-transfection in
2%CHAPS containing 150 mM NaCl, 50 mM Tris pH 8.0 and Com-
plete Protease Inhibitors. Cell lysates were immunoprecipitated
with anti-goat GFP antibody. Immune complexes were isolated
using protein A-Sepharose. The isolated immune complexes were
subjected to Western blot analysis.
Western blotting
Cell lysates were subjected to SDS polyacrylamide gel electro-
phoresis analysis and transferred to a polyvinylidene diﬂuoride
membrane (GE Healthcare). Following transfer, the membranes were
stained with antibodies to detect the indicated proteins. Antibodies
used for immunoblotting were as follows: mouse anti-cytochrome
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c (clone 6H2.B4; BD PharMingen), mouse anti-PARP (BD PharMin-
gen), mouse anti-Bak (BD PharMingen), mouse anti-EGFP (Covance),
mouse anti-FLAG M2 (Sigma), mouse anti-β-tubulin (ECM
Bioscience), and anti-I3L serum was provided by Dr. D. Evans
(University of Alberta, Edmonton, Alberta). Membranes were blotted
with donkey anti-mouse or anti-rabbit horseradish peroxidase-
conjugated antibodies (Jackson ImmunoResearch). Proteins were
visualized using enhanced chemiluminescence according to the
manufacturer's protocol (GE Healthcare).
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